CD BioGlyco is devoted to continuously optimizing the technology using our expertise for HMO production and supplies products on both bulk industry and R&D laboratory bulk industry scales. We will continue developing better solutions for HMO production to meet application challenges based on client requirements.
HMO consists of five structural units: an acid monosaccharide, sialic acidor N-acetylneuraminic acid; three monosaccharides, namely D-glucose (Glc), L-fucose (Fuc), and D-galactose (Gal); and an amino sugar, N-acetylglucosamine (GlcNAc). The reducing end structures of these units all contain a lactose moiety. HMOs can be divided into three categories: fucosylated oligosaccharides, sialylated oligosaccharides, and core oligosaccharides.
Fig.1 Structure of the main HMO produced and studied. (Pérez-Escalante, et al., 2020)
Oligosaccharides are formed from monosaccharide units whose degree of polymerization can vary from 3-10 to 2-20 monomers. The difference in the type of monosaccharide units and the degree of polymerization of oligosaccharides will affect their physical and chemical properties such as digestibility and viscosity. More importantly, this is related to different health benefits for humans. HMOs have attracted scientists' attention due to their many health functions.
They can act as bait and disrupt the binding of virus lectins or microorganisms with host cell receptors, thus preventing these organisms from infecting the host. They also regulate the epithelial and immune responses and reduce the excessive infiltration and activation of mucosal leukocytes, thereby reducing the risk of necrotizing enterocolitis. There is still a lot of room to explore their biological functions, which also provides more possibilities for developing the food market for vulnerable groups such as infants and the elderly. At the same time, HMO has also brought a lot of reference and research value for medicine, nutrition, and other fields.
CD BioGlyco provides manufacturing services in various aspects including chemical synthesis, whole-cell biotransformation (fermentation), enzyme biotransformation, and chemoenzymatic. In terms of HMO yield, biocatalytic methods are the most effective in market applications. For various known HMOs, we have corresponding synthetic methods to produce them which include:
We are also committed to developing more efficient and safer production methods and expanding the range of synthetic HMO species.
As one of the common suppliers of major pharmaceutical companies, CD BioGlyco provides clients with timely and accurate one-stop services for HMOs. If you are interested in our services, please contact us directly.
CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.